Ruyun Gao
Chinese Academy Of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory Of Clinical Study On Anticancer Molecular Targeted Drugs
Beijing, China
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
JAK3 A573V and JAK3 M511I mutations in peripheral T-cell lymphoma mediating resistance to anti-PD-1 therapy through the STAT3/PD-L1 pathway.
Journal: Journal for immunotherapy of cancer
Published: March 20, 2025
Multiomics and Single-Cell Insights Reveal a Lysophosphatidic Acid-Mediated Resistant Mechanism to Third-generation EGFR-TKI in Non-Small Cell Lung Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 17, 2025
Single-cell sequencing and spatial transcriptomics reveal FAS+ T cell and autophagy-related signatures predicting chemoimmunotherapy response in diffuse large B-cell lymphoma patients.
Journal: Science China. Life sciences
Published: December 10, 2024
Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997-2026).
Journal: Chinese medical journal
Published: September 23, 2024
Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI.
Journal: Scientific data
Published: July 19, 2024
DKK1+ tumor cells inhibited the infiltration of CCL19+ fibroblasts and plasma cells contributing to worse immunotherapy response in hepatocellular carcinoma.
Journal: Cell death & disease
Published: April 06, 2024
Mutational variant allele frequency profile as a biomarker of response to immune checkpoint blockade in non-small cell lung Cancer.
Journal: Journal of translational medicine
Published: April 06, 2024
A Novel IgG-IgM Autoantibody Panel Enhances Detection of Early-stage Lung Adenocarcinoma from Benign Nodules.
Journal: Genomics, proteomics & bioinformatics
Published: March 29, 2024
Evaluating plasma antinuclear autoantibody profile as a prognostic biomarker in lymphoma.
Journal: BMC cancer
Published: March 28, 2024
Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy.
Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: December 19, 2023
Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients.
Journal: Cancer immunology, immunotherapy : CII
Published: November 21, 2023
Development and validation of a deep learning-based model to predict response and survival of T790M mutant non-small cell lung cancer patients in early clinical phase trials using electronic medical record and pharmacokinetic data.
Journal: Translational lung cancer research
Published: November 12, 2023
Last Updated: 09/26/2026